BridgeBio Pharma logo

BridgeBio PharmaNASDAQ: BBIO

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

27 June 2019

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$4.79 B
-39%vs. 3y high
89%vs. sector
-vs. 3y high
-vs. sector
-491%vs. 3y high
6%vs. sector
-97%vs. 3y high
85%vs. sector

Price

after hours | Fri, 01 Nov 2024 23:09:37 GMT
$25.48+$2.07(+8.84%)

Dividend

No data over the past 3 years
$2.17 M$3.76 M
$2.17 M-$73.46 M

Analysts recommendations

Institutional Ownership

BBIO Latest News

3 Top Stocks That Could Still Rocket Higher in 2024
fool.com04 October 2024 Sentiment: POSITIVE

Upcoming Food and Drug Administration decisions could push these stocks through the roof.

BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions
globenewswire.com03 October 2024 Sentiment: POSITIVE

PALO ALTO, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, announced today that outcomes data through 42 months from the ongoing long-term open-label extension of ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be shared in a featured science oral presentation at the American Heart Association (AHA) Scientific Sessions, taking place in Chicago, Illinois on November 16 – 18, 2024. In addition to the presentation, BridgeBio was selected to share three posters in moderated poster sessions on ATTR-CM.

BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events
globenewswire.com27 September 2024 Sentiment: POSITIVE

- Acoramidis treatment led to a highly significant reduction in all-cause mortality (ACM) and recurrent cardiovascular-related hospitalizations (CVH) at Month 30 compared with placebo

3 Best High-Growth Mid-Cap Stocks to Buy in September 2024
247wallst.com18 September 2024 Sentiment: POSITIVE

Investors are optimistic that small- and mid-cap stocks will rally this year after a tough 2023, as attention shifts from the AI-focused Magnificent Seven.

BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA
globenewswire.com17 September 2024 Sentiment: POSITIVE

- Breakthrough Therapy Designation was granted based on preliminary clinical evidence from the PROPEL 2 clinical trial, meeting the FDA's requirement of potentially demonstrating substantial improvement in efficacy over available therapies on clinically significant endpoint(s)

BridgeBio to stop development of therapy for genetic disorder
reuters.com10 September 2024 Sentiment: NEGATIVE

BridgeBio Pharma said on Tuesday it will stop development of its experimental therapy for a genetic disease that affects the adrenaline-producing gland.

BridgeBio: With HELIOS-B Overhang Removed, Focus To Turn To Approval And Launch Of Acoramidis
seekingalpha.com31 August 2024 Sentiment: POSITIVE

BridgeBio's stock is underperforming this year despite the progress the company made in recent quarters. HELIOS-B trial of Alnylam's Amvuttra (vutrisiran) was keeping investors away from BridgeBio, but the data presentation this week should lift this overhang on the stock. Investor focus should turn to the potential FDA approval and launch of acoramidis for the treatment of ATTR CM, followed by three late-stage clinical readouts in 2025.

BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024
globenewswire.com29 August 2024 Sentiment: POSITIVE

PALO ALTO, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, announced today that additional data on clinical outcomes from ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be presented at the European Society of Cardiology (ESC) Congress 2024, taking place in London, United Kingdom on August 30 – September 2, 2024 and the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2024, taking place in Atlanta, Georgia on September 27 - 30, 2024.

BridgeBio Pharma to Participate in September Investor Events
globenewswire.com28 August 2024 Sentiment: POSITIVE

PALO ALTO, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that members of the management team will participate in the following upcoming investor conferences:

BridgeBio: PDUFA Date Expected In November 2024 Could Shift Momentum
seekingalpha.com22 August 2024 Sentiment: POSITIVE

The FDA accepted BridgeBio Pharma, Inc.'s NDA regulatory submission of Acoramidis for the treatment of patients with ATTR-CM and set a PDUFA date of November 29th of 2024. Partnership established with Bayer to commercialize Acoramidis for the treatment of patients with ATTR-CM in European territories; Regulatory approval for Europe expected in 2025. The transthyretin amyloidosis treatment market size is expected to reach $11.2 billion by 2032.

What type of business is BridgeBio Pharma?

BridgeBio Pharma, Inc. is a pharmaceutical company engaged in research and development of various drugs for genetic diseases. The company was founded in 2015, with its headquarters located in Palo Alto, California. BridgeBio Pharma's portfolio includes about 20 development programs for various products at different stages of development. The company's main candidates are: BBP-265, an oral low-molecular-weight transthyretin (TTR) intended for the treatment of transthyretin amyloidosis. Infigratinib, an oral selective FGFR1-3 tyrosine kinase inhibitor for the treatment of FGFR-driven cancer and achondroplasia. BBP-631, a preclinical gene transfer candidate product for the treatment of congenital adrenal hyperplasia (CAH) caused by 21OHD. BBP-454, a preclinical research program focused on new approaches to inhibiting KRAS for cancer treatment.

What sector is BridgeBio Pharma in?

BridgeBio Pharma is in the Healthcare sector

What industry is BridgeBio Pharma in?

BridgeBio Pharma is in the Biotechnology industry

What country is BridgeBio Pharma from?

BridgeBio Pharma is headquartered in United States

When did BridgeBio Pharma go public?

BridgeBio Pharma initial public offering (IPO) was on 27 June 2019

What is BridgeBio Pharma website?

https://bridgebio.com

Is BridgeBio Pharma in the S&P 500?

No, BridgeBio Pharma is not included in the S&P 500 index

Is BridgeBio Pharma in the NASDAQ 100?

No, BridgeBio Pharma is not included in the NASDAQ 100 index

Is BridgeBio Pharma in the Dow Jones?

No, BridgeBio Pharma is not included in the Dow Jones index

When was BridgeBio Pharma the previous earnings report?

No data

When does BridgeBio Pharma earnings report?

Next earnings report date is not announced yet